Skip to main content
AVTRAvantor, Inc.Sell4.9·$9.63+2.61%
Open full analysis

Avantor, Inc. (AVTR) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Engine safety override at $9.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Elevated put/call ratio: 3.12; Below-average business quality; Negative price momentum.

Avantor distributes laboratory supplies and manufactures specialty materials — J.T. Baker high-purity chemicals, NuSil silicone, and Masterflex fluid systems — to 300,000+ customer locations in ~180 countries through Laboratory Solutions and Bioscience Production segments. The... Read more

$9.63+2.3% A.UpsideScore 4.9/10#19 of 26 Medical Instruments & Supplies
QualityF-score8 / 9FCF yield7.63%
Stop $8.96Target $9.86(resistance)A.R:R -0.7:1
Analyst target$9.67+0.4%15 analysts
$9.86our TP
$9.63price
$9.67mean
$7
$19

Sell if holding. Engine safety override at $9.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Elevated put/call ratio: 3.12; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 70. Score 4.9/10, moderate confidence.

Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-15
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Fri, Jul 31, 202645d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: sole-sourced raw materials
Target reached (-9.7% upside)
Quality below floor (3.1 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)11.0
Mkt Cap$6.4B
EV/EBITDA10.5
Profit Mgn-8.4%
ROE-9.4%
Rev Growth0.0%
Beta0.96
DividendNone
Rating analysts25

Quality Signals

Piotroski F8/9

Options Flow

P/C3.13bearish
IV92%elevated
Max Pain$1-89.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSuppliersole-sourced raw materials
    10-K Item 1A: 'raw materials, many of which are sole-sourced due to market or customer demands'

Material Events(8-K, last 90d)

  • 2026-04-01Item 5.02HIGH
    CFO R. Brent Jones resigned March 26, 2026 to join a company outside life sciences (90-day notice required). SVP/CAO Steven Eck named interim CFO; executive search for permanent CFO underway. No permanent successor named.
    SEC filing →
  • 2026-04-23Item 5.02MEDIUM
    EVP Benoit Gourdier notified April 17, 2026 of transition to segment integration role, expected to depart by Dec 31, 2026. Successor Ludovic Brellier named EVP Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

5 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
1.6
52w Position
2.1
Bollinger
2.6
Gap
5.0

Unprofitable operations — net margin -8.4%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Roa
1.9
Gross Margin
2.4
Operating Margin
2.5
Moat
3.2
Current Ratio
6.3
Piotroski F
8.9
No competitive moatStrong Piotroski F-Score: 8/9

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Earnings Timing
5.0
Erm
7.5
Estimates up 18.9% (30d)Earnings concerns: 1B/3M

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Rsi
3.0
Ma Position
6.0
Macd
7.6
Overbought bear rally (RSI 70)Volume distribution (falling OBV)Below 200-MA, MA slope -5.7%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.6
Growth Rank
5.0
Value Rank
8.8
GatesMomentum 3.5<4.5A.R:R -0.7=NEGATIVEDeath cross (50MA < 200MA)Executive change: officer departure/appointmentInsider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 45d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
70 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $7.42Resistance $10.06

Price Targets

$9
$10
A.Upside+2.4%
A.R:R-0.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-9.7% upside)
! Quality below floor (3.1 < 4.0)
! momentum at 3.5 (below the engine's 4.5 threshold)

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-31 (45d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AVTR stock a buy right now?

Sell if holding. Engine safety override at $9.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Elevated put/call ratio: 3.12; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 70. Prior stop was $8.96. Score 4.9/10, moderate confidence.

What is the AVTR stock price target?

Take-profit target: $9.86 (+2.3% upside). Prior stop was $8.96. Stop-loss: $8.96.

What are the risks of investing in AVTR?

Concentration risk — Supplier: sole-sourced raw materials; Target reached (-9.7% upside); Quality below floor (3.1 < 4.0).

Is AVTR overvalued or undervalued?

Avantor, Inc. trades at a P/E of N/A (forward 11.0). TrendMatrix value score: 7.7/10. Verdict: Sell.

What do analysts say about AVTR?

25 analysts cover AVTR with a consensus score of 3.3/5. Average price target: $10.

What does Avantor, Inc. do?Avantor distributes laboratory supplies and manufactures specialty materials — J.T. Baker high-purity chemicals, NuSil...

Avantor distributes laboratory supplies and manufactures specialty materials — J.T. Baker high-purity chemicals, NuSil silicone, and Masterflex fluid systems — to 300,000+ customer locations in ~180 countries through Laboratory Solutions and Bioscience Production segments. The company generates revenue through distribution and service contracts, with ~80% of 2025 transactions via digital channels and no single customer exceeding 5% of net sales.

Related stocks: NVST (Envista Holdings Corporation) · WST (West Pharmaceutical Services, I) · RMD (ResMed Inc.) · LMAT (LeMaitre Vascular, Inc.) · MMED (MiniMed Group, Inc.)
Home Stocks AVTR

Latest news

Latest News

Benzinga8d ago
Benzinga14d ago
Benzinga19d ago
Benzinga32d agoAnalyst
Benzinga46d agoAnalyst
Benzinga47d agoAnalyst
Benzinga48d agoEarnings
Benzinga48d agoEarnings
Benzinga48d agoEarnings
Benzinga48d ago
Benzinga62d agoAnalyst
Benzinga64d agoProduct
Benzinga68d ago